Brookfield Asset Management Inc. Blueprint Medicines Corp Transaction History

Brookfield Asset Management Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $607,548 - $945,453	-12,168 Reduced 16.59%	61,165 $4.03 Million
Q2 2022 Nov 16, 2022	BUY	$45.23 - $70.15 $550,358 - $853,585	12,168 Added 19.89%	73,333 $3.7 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $2.8 Million - $4.34 Million	61,919 Added 542.48%	73,333 $3.7 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $1.08 Million - $1.32 Million	11,414 New	11,414 $1.22 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.